Watton Corey Michael 4

What Happened
Corey Michael Watton, a director of Zevra Therapeutics, was granted a derivative award covering 30,000 shares on June 4, 2026. The award was reported as acquired at $0.00 (i.e., no cash paid to receive the grant); the exercise price is equal to the closing price of ZVRA common stock on the Nasdaq Global Select Market on the grant date. This is a compensation grant to a non-employee director rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-18).
• Grant: 30,000 shares (derivative award/option). Acquisition price listed as $0.00; exercise price = closing Nasdaq price on 6/4/2026 (per footnote).
• Vesting: 100% of shares vest on the earlier of (i) first anniversary of grant, (ii) day before the first annual meeting after grant, or (iii) immediately prior to a change in control — in each case subject to continued service.
• Purpose: Awarded as non-employee director compensation under the company’s director compensation policy.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: The Form 4 was filed 14 days after the grant date (appears outside the typical 2-business-day filing window for Form 4).

Context
This was a standard director option/award as part of board compensation. Because the exercise price equals the market close on the grant date, the options have no intrinsic value at grant; they will only gain value if the stock price rises above the exercise price before exercise. The award does not represent an immediate purchase or sale of shares and should be viewed as compensation rather than a direct trading signal.